SK279292B6 - Benzimidazolové deriváty 5-ht1a a 5-ht2 antagonist - Google Patents

Benzimidazolové deriváty 5-ht1a a 5-ht2 antagonist Download PDF

Info

Publication number
SK279292B6
SK279292B6 SK101-94A SK10194A SK279292B6 SK 279292 B6 SK279292 B6 SK 279292B6 SK 10194 A SK10194 A SK 10194A SK 279292 B6 SK279292 B6 SK 279292B6
Authority
SK
Slovakia
Prior art keywords
formula
compound
dihydro
group
benzimidazol
Prior art date
Application number
SK101-94A
Other languages
English (en)
Slovak (sk)
Other versions
SK10194A3 (en
Inventor
Giuseppe Bietti
Franco Borsini
Mario Turconi
Ettore Giraldo
Maura Bignotti
Original Assignee
Boehringer Ingelheim Italia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Italia S.P.A. filed Critical Boehringer Ingelheim Italia S.P.A.
Publication of SK10194A3 publication Critical patent/SK10194A3/sk
Publication of SK279292B6 publication Critical patent/SK279292B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
SK101-94A 1991-07-30 1992-07-30 Benzimidazolové deriváty 5-ht1a a 5-ht2 antagonist SK279292B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI912118A IT1251144B (it) 1991-07-30 1991-07-30 Derivati del benzimidazolone
PCT/IT1992/000088 WO1993003016A1 (en) 1991-07-30 1992-07-30 Benzimidazolone derivatives as 5-ht1a and 5-ht2 antagonists

Publications (2)

Publication Number Publication Date
SK10194A3 SK10194A3 (en) 1994-12-07
SK279292B6 true SK279292B6 (sk) 1998-09-09

Family

ID=11360463

Family Applications (1)

Application Number Title Priority Date Filing Date
SK101-94A SK279292B6 (sk) 1991-07-30 1992-07-30 Benzimidazolové deriváty 5-ht1a a 5-ht2 antagonist

Country Status (31)

Country Link
US (1) US5576318A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0526434B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2989667B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100263495B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE191910T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU665366B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2114542C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ281511B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69230926T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0526434T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE03070B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2144412T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI111460B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3033947T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUT70195A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE922464A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL102665A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1251144B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9204139A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO304070B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ243777A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH30998A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL171329B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT526434E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2096411C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG52407A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK279292B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW209862B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA42684C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1993003016A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA925682B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
SE9201138D0 (sv) * 1992-04-09 1992-04-09 Astra Ab Novel phthalimidoalkylpiperazines
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
DE69427289T2 (de) * 1993-03-16 2001-09-06 Pfizer Inc., New York Naphtalinderivate
JP3719612B2 (ja) * 1993-06-14 2005-11-24 塩野義製薬株式会社 ヘテロ環を含有する尿素誘導体
IL114027A (en) * 1994-06-08 1999-11-30 Lundbeck & Co As H 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them
EP0765320B1 (en) * 1994-06-14 2001-10-10 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
KR970704698A (ko) * 1994-08-05 1997-09-06 스피겔 알렌 제이 도파민 작용 활성을 갖는 벤즈이미다졸 유도체(benzimidazole derivatives having dopaminergic activity)
US5883094A (en) * 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
US5889010A (en) * 1995-05-18 1999-03-30 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
WO1997016187A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
US6376494B1 (en) 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
JP2002518382A (ja) * 1998-06-15 2002-06-25 アメリカン・ホーム・プロダクツ・コーポレイション セロトニン作動薬としてのシクロアルキル−置換アリール−ピペラジン、ピペリジンおよびテトラヒドロピリジン
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US6521623B1 (en) 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
ES2273891T3 (es) * 2000-09-19 2007-05-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Nuevos derivados de bencimidazolona que presentan actividad en los receptores de serotonina y dopamina.
WO2002024661A2 (en) * 2000-09-19 2002-03-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
EP1408976B3 (en) 2001-07-20 2010-08-25 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
EP1414816B1 (en) * 2001-08-02 2005-02-09 BIDACHEM S.p.A. Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
CN101002780A (zh) * 2002-05-22 2007-07-25 贝林格尔英格海姆法玛两合公司 新型含氟班色林多晶型物a的药物组合物
EA200500342A1 (ru) * 2002-09-17 2005-08-25 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Гетероциклические замещённые пиперазины для лечения шизофрении
CN100482659C (zh) * 2003-09-03 2009-04-29 辉瑞大药厂 具有5-ht4受体激动活性的苯并咪唑酮化合物
AR045843A1 (es) * 2003-10-03 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolonas y quinazolinonas sustituidas con hidronopol como agonistas en receptores orl 1 humanos
MXPA06012059A (es) * 2004-04-22 2007-01-25 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii.
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
BRPI0512046A (pt) * 2004-06-15 2008-02-06 Pfizer derivados de ácido benzimidazolona carboxìlico
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US20060014757A1 (en) * 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
JP2008511569A (ja) * 2004-09-03 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 注意欠如活動過多障害の治療方法
CA2598536C (en) * 2005-02-22 2011-04-05 Pfizer Inc. Oxyindole derivatives as 5ht4 receptor agonists
CA2599937A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
EP1858516A1 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International GmbH Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
US20060264511A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
CA2608713A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
RU2415138C2 (ru) * 2005-07-13 2011-03-27 Ф. Хоффманн-Ля Рош Аг Производные бензимидазола и индола в качестве селективных антагонистов 5-нт6 и/или 5-нт2а рецепторов
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US7790726B2 (en) * 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US7923449B2 (en) 2005-10-29 2011-04-12 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2007096300A1 (en) * 2006-02-20 2007-08-30 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of urinary incontinence
WO2007099828A1 (ja) * 2006-02-23 2007-09-07 Shionogi & Co., Ltd. 環式基で置換された含窒素複素環誘導体
CA2642368A1 (en) * 2006-02-28 2007-09-07 Boehringer Ingelheim International Gmbh Treatment of prevention of valvular heart disease with flibanserin
KR20090005371A (ko) * 2006-05-09 2009-01-13 베링거 인겔하임 인터내셔날 게엠베하 폐경후 성욕 장애의 치료를 위한 플리반세린의 용도
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
WO2008006838A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
MX2009001551A (es) 2006-08-14 2009-02-20 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas.
BRPI0716436B8 (pt) 2006-08-25 2021-05-25 Boehringer Ingelheim Int sistema de liberação controlada e método para fabricação do mesmo
US8722682B2 (en) 2006-12-20 2014-05-13 Sprout Pharmaceuticals, Inc. Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity
WO2008090742A1 (ja) * 2007-01-23 2008-07-31 National University Corporation Hokkaido University 眼疾患モデル用非ヒト動物
US8198307B2 (en) 2007-05-11 2012-06-12 Korea Research Institute Of Chemical Technology Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same
CL2008002693A1 (es) * 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
US20110028490A1 (en) * 2008-01-24 2011-02-03 Neurosearch A/S 4-phenyl-piperazin-1-yl-alkyl-benzoimidazol-2-one derivatives and their use as monoamine neurotransmitter re-uptake in-hibitors
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
CA2686480A1 (en) * 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
WO2010146595A2 (en) * 2009-06-16 2010-12-23 Symed Labs Limited Novel polymorphs of flibanserin hydrochloride
BRPI1003506B1 (pt) 2010-09-24 2019-12-03 Ache Int Bvi Ltd composto alquil-piperazino-fenil-4(3h)quinazolinonas e uso do composto alquil-piperazino-fenil-4(3h)quinazolinonas associado aos receptores serotoninérgicos 5-ht1a e 5-ht2a
JP6448541B2 (ja) * 2012-10-11 2019-01-09 サザン リサーチ インスティテュート アミノアルキルピペラジンの尿素及びアミド誘導体並びにその使用
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017076213A1 (zh) * 2015-11-02 2017-05-11 苏州旺山旺水生物医药有限公司 苯并咪唑类化合物、其制备方法及用途
WO2017076356A1 (zh) * 2015-11-05 2017-05-11 苏州晶云药物科技有限公司 氟班色林的新晶型及其制备方法
CN106749038A (zh) * 2015-11-25 2017-05-31 山东诚创医药技术开发有限公司 一种氟班色林的制备方法
CN106866546A (zh) * 2015-12-10 2017-06-20 常州爱诺新睿医药技术有限公司 氟班色林或其药学上可接受的盐与药用辅料的固体分散体及其制备方法
WO2017128932A1 (zh) 2016-01-31 2017-08-03 孟晓明 氟班色林的新晶型及其制备方法及其用途
WO2017133337A1 (zh) * 2016-02-02 2017-08-10 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑酮化合物及包含该化合物的组合物
CN107235913B (zh) * 2016-03-29 2020-07-10 苏州科伦药物研究有限公司 工业规模高效制造优质氟班色林的方法
CN106866582A (zh) * 2017-01-10 2017-06-20 广州隽沐生物科技有限公司 一种氟班色林中间体的制备方法
HU231283B1 (hu) 2018-08-01 2022-09-28 Richter Gedeon Nyrt Eljárás a flibanserin többlépéses folyamatos áramú előállítására
CA3211341A1 (en) * 2021-03-19 2022-09-22 Centre National De La Recherche Scientifique Applications of biased ligands of the serotonin 5-ht7 receptor for the treatment of pain, multiple sclerosis and the control of thermoregulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3406178A (en) * 1964-02-04 1968-10-15 Monsanto Chem Australia Ltd Preparation of 2-substituted benzimidazoles
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
YU39992B (en) * 1976-04-02 1985-06-30 Janssen Pharmaceutica Nv Process for obtaining new piperazine and piperidine derivatives
AU521110B2 (en) * 1978-06-20 1982-03-18 Synthelabo Phenylpiperazine derivatives
IT1176613B (it) * 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
HUT43600A (en) * 1985-06-22 1987-11-30 Sandoz Ag Process for production of new thiazole derivatives and medical compound containing those
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US5036088A (en) * 1986-06-09 1991-07-30 Pfizer Inc. Antiallergy and antiinflammatory agents, compositions and use
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4954503A (en) * 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
AU2427592A (en) 1993-03-02
DE69230926D1 (de) 2000-05-25
IE922464A1 (en) 1993-02-10
KR100263495B1 (ko) 2000-11-01
ATE191910T1 (de) 2000-05-15
SG52407A1 (en) 1998-09-28
PL171329B1 (pl) 1997-04-30
RU2096411C1 (ru) 1997-11-20
TW209862B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-07-21
FI940420A0 (fi) 1994-01-28
HUT70195A (en) 1995-09-28
IL102665A (en) 1996-10-31
ZA925682B (en) 1994-01-31
CZ17094A3 (en) 1994-05-18
HU9400255D0 (en) 1994-05-30
HU211256A9 (en) 1995-11-28
FI940420A7 (fi) 1994-01-28
CZ281511B6 (cs) 1996-10-16
DK0526434T3 (da) 2000-07-17
NO304070B1 (no) 1998-10-19
NO940306L (no) 1994-03-14
PH30998A (en) 1997-12-23
EP0526434A1 (en) 1993-02-03
PL302163A1 (en) 1994-07-11
EE03070B1 (et) 1998-02-16
FI111460B (fi) 2003-07-31
JPH06509575A (ja) 1994-10-27
GR3033947T3 (en) 2000-11-30
UA42684C2 (uk) 2001-11-15
ES2144412T3 (es) 2000-06-16
US5576318A (en) 1996-11-19
IT1251144B (it) 1995-05-04
AU665366B2 (en) 1996-01-04
CA2114542C (en) 2004-02-24
ITMI912118A1 (it) 1993-01-31
SK10194A3 (en) 1994-12-07
DE69230926T2 (de) 2000-10-05
JP2989667B2 (ja) 1999-12-13
WO1993003016A1 (en) 1993-02-18
NZ243777A (en) 1995-04-27
CA2114542A1 (en) 1993-02-18
HK1010725A1 (en) 1999-06-25
EP0526434B1 (en) 2000-04-19
PT526434E (pt) 2000-08-31
MX9204139A (es) 1993-01-01
NO940306D0 (no) 1994-01-28
ITMI912118A0 (it) 1991-07-30

Similar Documents

Publication Publication Date Title
SK279292B6 (sk) Benzimidazolové deriváty 5-ht1a a 5-ht2 antagonist
EP1218352B1 (en) Benzimidazolone derivatives having mixed serotonine and dopamine receptors affinity
US6521623B1 (en) N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US5159083A (en) Certain aminomethyl phenylimidazole derivatives; a class of dopamine receptor subtype specific ligands
US5834493A (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
JPH0314563A (ja) 新規４―フルオロ安息香酸誘導体
CA2529445A1 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
SK96494A3 (en) Piperazine and piperidine derivatives, and their use as antipsychotic
CZ20022880A3 (cs) Deriváty chinolinu jako alfa 2 antagonisté
JPH05194441A (ja) 新規な置換３−ピペラジニルアルキル−２，３−ジヒドロ−４ｈ−１，３−ベンゾオキサジン−４−オン、その製造法および治療用途
JPH01128970A (ja) 新規複素環誘導体
EP0444924B1 (en) Fused 7-membered cyclic compound and antipsychotic preparation containing the same
JPH0573742B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
US5420130A (en) 2-aminopyrazine-5-carboxamide derivatives, their preparation and their application in therapeutics
US20010046991A1 (en) Derivatives of quinoline as alpha-2 antagonists
HK1010725B (en) Benzimidazolone derivatives as 5-ht1a and 5-ht2 antagonists
US7371769B2 (en) Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
CA2587936A1 (en) Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites
WO2000018763A2 (en) 2-(2,3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands
HU195649B (en) Process for producing oxazepinone derivatives condensed with aromatic ring and their sulfur analogs